ROCK2 and Alzheimer disease: As decreased miR-135a-5p levels have been observed in the gray matter of patients with AD46 and Rock2 levels are increased in the earliest stages of AD and remain elevated throughout disease progression, our study proposed a therapeutic target for overcoming synaptic and memory deficits in AD.